Journal List > Tuberc Respir Dis > v.52(6) > 1062108

TOOLS
Chung, Park, Cheong, Kim, Chang, Kim, Kwak, Kim, and Kim: Comparison of OK-432 and Doxycycline Pleurodesis for Malignant Pleural Effusions Caused by Lung Cancer
Original Article

Tuberculosis and Respiratory Diseases 2002; 52(6): 590-596.

Published online: 30 June 2002

DOI: https://doi.org/10.4046/trd.2002.52.6.590

Comparison of OK-432 and Doxycycline Pleurodesis for Malignant Pleural Effusions Caused by Lung Cancer

Jae Ho Chung, M.D.1, Moo Suk Park, M.D.1, Jae Hee Cheong, M.D.1, Young Sam Kim, M.D.1, 2, Joon Chang, M.D.1, 2, Joo Hang Kim, M.D.1, 2, 3, Seung Min Kwak, M.D.5, Sung Kyu Kim, M.D.1, 2, Se Kyu Kim, M.D.1, 2, 3, 4

1Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.

2The Institute of Chese Disease, Yonsei University College of Medicine, Seoul, Korea.

3Brain Korea 21 Project for Medical Sciences, Yonsei University College of Medicine, Seoul, Korea.

4Cancer Metastasis Research Center, Yonsei University College of Medicine, Seoul, Korea.

5Department of Internal Medicine, College of Medicine, Inha University, Sungnam, Korea.

Address for correspondence (sekyukim@yumc.yonsei.ac.kr)

Copyright©2002. The Korean Academy of Tuberculosis and Respiratory Diseases. All rights reserved.

Abstract

Background

Lung cancer is the leading cause of malignant pleural effusions, which is currently most commonly treated using pleurodesis via bedside thoracostomy. Several agents had been used for the treatment of pleural sclerosis, but with differing efficacies and associated side effects. Our purpose with this study was to compare the efficacy, side effects and disease free survival times of patients being treated with OK-432 and doxycycline sclerotherapy in lung cancer induced malignant pleural effusions.

Patients and Methods

79 patients who underwent pleurodesis with OK-432 and doxycycline, between Jan. 1994 and Aug. 2001, were retrospectively reviewed. Resopnses 30 days following pleurodesis were determined from chest radiographs, with the disease free survival time being evaluated according to the response.

Results

The success rates, 30 day followint pleurodesis, with OK-432 and doxycycline 83 and 87%, respectively (p=0.677). With regard to the side effects, fever was more common when OK-432 was used (59%, p=0.001), and pain was more common with doxycycline use (73%, p=0.008). There was no significant difference in disease free survival times between OK-432 (13.6 Months) and doxycycline (11.6 Months) (p=0.532).

Conclusions

with the use of OK-432, for pleurodesis, was as effective as doxycycline, can be considered as an alternative treatment for malignant effusion in patients with lung cancer.

Keywords: OK-432, Doxycycline, Pleurodesis

TOOLS
Similar articles